Exagen appoints Jeffrey Black as CFO; Kamal Adawi steps down

EXAGEN INC.

Jeffrey G. Black named CFO effective Sept 1, 2024; replaces Kamal Adawi.
John Aballi serves as interim CFO from July 31 until Black's start.
Black receives $460K base salary, $125K signing bonus, and up to 225K RSUs.
Black previously CFO at Standard BioTools, Apollo Endosurgery, and Alphatec Spine.
Adawi entitled to severance as Tier 2 participant under company's severance plan.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jeffrey Black

Chief Financial Officer

XGN · EXAGEN INC.

Effective: 2024-09-01
Filed: August 2, 2024, 7:59 PM ET

On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.

Departed

Kamal Adawi

Chief Financial Officer and Corporate Secretary

XGN · EXAGEN INC.

Effective: 2024-07-31
Successor: John Aballi
Filed: August 2, 2024, 7:59 PM ET

On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.

Appointed (interim)

John Aballi

Interim Chief Financial Officer

XGN · EXAGEN INC.

Effective: 2024-07-31
Filed: August 2, 2024, 7:59 PM ET

John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeffrey Black was appointed as Chief Financial Officer at EXAGEN INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On July 25, 2024, Exagen Inc. (the “Company”) appointed, effective as of September 1, 2024, Jeffrey Black to serve as the Company’s Chief Financial Officer and principal financial officer for SEC reporting purposes.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kamal Adawi departed as Chief Financial Officer and Corporate Secretary at EXAGEN INC..

Action: no longer serves
Role: Chief Financial Officer and Corporate Secretary

Exact text from the filing

On July 31, 2024, the Company also announced that John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi who no longer serves as Chief Financial Officer and Corporate Secretary of the Company, effective as of July 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John Aballi was appointed as Interim Chief Financial Officer at EXAGEN INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

John Aballi had been appointed as Interim Chief Financial Officer of the Company, replacing Kamal Adawi

View on SEC.gov

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-24-000071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.